Alaunos CEO receives stock grant instead of salary

Alaunos Therapeutics Chief Executive Officer Holger Weis received a stock grant as compensation.

Accepted by SEC EDGAR 07/02/2026 - 05:33 PM EDT

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Alaunos Therapeutics Chief Executive Officer Holger Weis received a stock grant as compensation. On June 30, 2026, he acquired 3,880 shares of Alaunos common stock at $2.26 per share in a grant issued in lieu of net salary. Following this award, he directly holds 16,552 common shares, and no derivative positions are reported in this filing.

Insider Trade Summary

Grant/Award: 3,880 shares

Grant/Award 1 txn

Insider Weis Holger

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	3,880	$2.26	$9K

Holdings After Transaction: Common Stock — 16,552 shares (Direct)

Footnotes (1)

F1. Represents shares of common stock issued in lieu of net salary.

Key Figures

Shares granted: 3,880 shares Grant price: $2.26 per share Shares held after grant: 16,552 shares

3 metrics

Shares granted 3,880 shares Common stock grant on June 30, 2026

Grant price $2.26 per share Value assigned to the 3,880-share grant

Shares held after grant 16,552 shares Total direct common shares after the transaction

Key Terms

grant/award acquisition, in lieu of net salary, Common Stock, Form 4

4 terms

grant/award acquisition financial

"transaction_action: "grant/award acquisition" for the 3,880-share entry"

in lieu of net salary financial

"Represents shares of common stock issued in lieu of net salary."

Common Stock financial

"security_title: "Common Stock" for the reported transaction"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4): Alaunos Therapeutics, Inc."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Alaunos Therapeutics (TCRT) disclose for CEO Holger Weis?

Alaunos Therapeutics disclosed that CEO Holger Weis received 3,880 shares of common stock as a grant. The shares were issued on June 30, 2026, in lieu of net salary, reflecting compensation rather than an open-market stock purchase or sale.

How many Alaunos Therapeutics (TCRT) shares did the CEO receive and at what price?

CEO Holger Weis received 3,880 shares of Alaunos common stock valued at $2.26 per share. This transaction is classified as a grant or award acquisition, representing equity-based compensation instead of cash salary, according to the Form 4 disclosure and its accompanying footnote.

Was the Alaunos Therapeutics (TCRT) CEO’s Form 4 transaction an open-market buy or sell?

The transaction was not an open-market buy or sell. It is reported as a grant or award acquisition of 3,880 common shares issued in lieu of net salary, meaning the CEO received stock as compensation rather than trading shares on the open market.

How many Alaunos Therapeutics (TCRT) shares does CEO Holger Weis hold after this transaction?

After receiving the 3,880-share grant, CEO Holger Weis directly holds 16,552 shares of Alaunos common stock. This post-transaction holding figure is reported in the Form 4 as the total number of common shares he owns directly following the award.

What does “issued in lieu of net salary” mean in the Alaunos (TCRT) CEO’s stock grant?

“Issued in lieu of net salary” means the CEO received company stock instead of cash for part of his compensation. In this case, 3,880 Alaunos common shares were granted as payment, converting salary into equity rather than a traditional cash payroll payment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Weis Holger

(Last)

(First)

(Middle)

C/O ALAUNOS THERAPEUTICS, INC.

501 E. LAS OLAS BLVD. SUITE 300

(Street)

FORT LAUDERDALE

FLORIDA

33301

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Alaunos Therapeutics, Inc. [ TCRT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/30/2026		A		3,880⁽¹⁾	A	$2.26	16,552	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares of common stock issued in lieu of net salary.

	/s/ Weis, Holger	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR